MYOV News and Press, Myovant Sciences Ltd. From 01/04/21

BASEL, Switzerland, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced the appointment of David Marek as chief executive officer of Myovant Sciences, Inc. Mr. Marek will also ...

Should Investors Be Watching These Top Biotech Stocks Right Now? 3 Names To Consider The coronavirus pandemic has thrown several top biotech stocks into the limelight this year. They include biotech companies that are currently in the coronavirus vaccine race like Pfizer ( PFE...

Shares of Myovant Sciences (NYSE: MYOV) were soaring 26.7% as of 11:17 a.m. EST on Monday. The big gain came after Myovant and Pfizer (NYSE: PFE) announced a collaboration to develop and market relugolix in the U.S. and Canada in women's health and as a treatment for prostat...

Myovant Sciences (MYOV) jumps 22% premarket after collaborating with Pfizer (PFE) to develop and commercialize relugolix – a once-daily, oral gonadotropin-releasing hormone (GnRH) receptor antagonist – in oncology (prostate cancer) and women’s health in the U.S....

AeroCentury (ACY) +172%.Ocugen (OCGN) +43%.Aqua Metals (AQMS) +39%.Nxt-ID (NXTD) +32%.Marathon Patent Group (MARA) +28%.Peabody Energy (BTU) +25%.Phunware (PHUN) +25%.Osmotica Pharmaceuticals (OSMT) +22%.Ashford Hospitality Trust (AHT) +22% after securing commitment for $200M corporate f...

Myovant and Pfizer to jointly develop and commercialize ORGOVYX™ (relugolix) and relugolix combination tablet and share profits and expenses in the U.S. and Canada Myovant to receive an upfront payment of $650 million in addition to potential regulatory and sales mi...

Riding strong data, Myovant recently secured FDA approval for relugolix in treating advanced prostate cancer. Under the brand Orgovyx, Myovant will market the said drug as soon as in January. The Orgovyx launch is interesting because of patients favoring the oral pill, especially ...

Baird raises the price target for Myovant Sciences (MYOV) to $30 from $24 after the company’s ORGOVYX™ (relugolix), an oral treatment for advanced prostate cancer in adults, won FDA approval.The market launch expected in January 2021 for the first and only oral gonadot...

ORGOVYX demonstrated a 96.7% response rate in testosterone suppression to castrate levels (< 50 ng/dL) through 48 weeks in the Phase 3 HERO study Conference call and webcast to be held on December 21 at 8:30 a.m. Eastern Time / 5:30 a.m. Pacific Time BASEL, ...

The FDA has announced it has granted the approval to Myovant Sciences (MYOV) for Orgovyx (relugolix) in the treatment of adult patients with advanced prostate cancer.Richard Pazdur, M.D., the Director of the FDA's Oncology Center of Excellence, said, “Today's approval marks t...